Wordt geladen...
Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier
The clinical application of dipeptidyl peptidase IV inhibitors (DPP4i) increasing active glucagon-like peptide-1 (AGLP-1) levels has been linked to pancreatitis, pancreatic tumors, and cardiovascular events. However, DPP4 mutations in humans or the long-term outcomes of high glucagon-like peptide-1...
Bewaard in:
| Gepubliceerd in: | Front Endocrinol (Lausanne) |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Frontiers Media S.A.
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5845420/ https://ncbi.nlm.nih.gov/pubmed/29556215 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2018.00062 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|